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Abstract
Background: Although various studies have demonstrated efficacy of DNA-recombinant anti-
hepatitis B vaccines, their effectiveness in health care settings has not been researched adequately.
This gap is particularly visible for blood donors, a group of significant importance in the reduction
of transfusion-transmitted hepatitis B.
Methods: This is a double cohort study of 1411 repeat blood donors during the period 1998–
2002, involving a vaccinated and an unvaccinated cohort, with matching of the two in terms of sex,
age and residence. Average follow-up was 3.17 person-years. The outcome measure was infection
with hepatitis B virus (HBV), defined by testing positive on serologic markers HBsAg or anti-HBC.
All blood donors were from the blood bank in Joaçaba, federal state of Santa Catarina, Brazil.
Results: The cohorts did not differ significantly regarding sex, age and marital status but the
vaccinated cohort had higher mean number of blood donations and higher proportion of those
residing in the county capital Joaçaba. Hepatitis B incidences per 1000 person-years were zero
among vaccinated and 2,33 among non-vaccinated, resulting in 100% vaccine effectiveness with 95%
confidence interval from 30,1% to 100%. The number of vaccinated persons necessary to avoid one
HBV infection in blood donors was estimated at 429 with 95% confidence interval from 217 to
21422.
Conclusion: The results showed very high effectiveness of DNA-recombinant anti-HBV vaccines
in blood donors. Its considerable variation in this study is likely due to the limited follow-up and
the influence of confounding factors normally balanced out in efficacy clinical trials.
Background
There is a wide consensus that vaccination against hepati-
tis B virus (HBV) is the best cost-effective measure to com-
bat the disease [1]. In Brazil, its burden is grossly
underestimated due to the epidemiologic surveillance
which captures primarily severe cases in need of hospital
treatment while missing the long term consequences of
HBV infection such as cirrhoses and hepatocelular carci-
noma. It has been estimated that vaccinating children
against HBV in developing countries would prevent loss
of three million lives each year, as well as 60–80% of cases
of hepatocelular carcinoma [1-3]. More than 150 coun-
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tries have already given high priority to the vaccination
programs against HBV [3], but some of them, including
Brazil, have not fully implemented such programs.
Brazil has recently started producing a DNA-recombinant
anti-HBV vaccine whose immunogenicity has been con-
firmed in several studies [4-7]. However, its effectiveness
in reducing HBV incidence in health care settings has not
been adequately researched. This gap is particularly visible
regarding blood donors – a group of special importance in
preventing HBV transmission and therefore explicitly tar-
geted for immunization at any age according to the guide-
lines of the Brazilian Ministry of Health [8].
Although the residual risk of not detecting HBV by routine
serologic screening in the largest blood bank in the state
capital Florianopolis has been reduced considerably in
the decade of 1990, it remains at a level approximately
hundred times higher than in the developed countries
[9,10], thus seriously undermining transfusion recipient
safety. Another reason to strongly encourage vaccination
among blood donors and verify its effectiveness is recent
evidence of a high risk group using blood bank serologic
screening to check their HIV status due to the guarantee of
obtaining an anonymous, free of charge and rapidly deliv-
ered test result in this health setting [10,11].
The aim of this study is to evaluate the effectiveness of
DNA-recombinant anti-HBV vaccines among blood
donors in an endemic area in Brazil. Although there are
no reasons to believe that the vaccine efficacy in blood
donors should be much different from that of other
healthy adults, its effectiveness may not necessarily follow
this logic because it is highly susceptible to selection bias
within a particular setting. In the blood donor context,
this bias may arise because the main protection factor
(getting vaccinated) is likely to be influenced by a more
general attitude towards health which also reduces risk
behavior for HBV infection. Differently from a rand-
omized controlled trial of vaccine efficacy, it would be
ethically unacceptable to randomly allocate anti-HBV vac-
cine to blood donors because its protective effect has
already been proven beyond any doubt. It is therefore nec-
essary to make post hoc adjustment for risk factor imbal-
ances between vaccinated and non-vaccinated blood
donors in order to evaluate the benefit of the vaccine
achieved in a particular health care setting, i.e. the vaccine
effectiveness. The results can then be compared to those
achieved in randomized controlled trials of vaccine effi-
cacy in healthy adults which can be considered an upper
bound for vaccine effectiveness.
Methods
A retrospective double-cohort study [12] was used to esti-
mate the protective effect of anti-HBV vaccination by com-
paring the incidence of HBV infection in the vaccinated
and the non-vaccinated cohort of repeat blood donors.
For the purpose of this study, case definition of HBV infec-
tion was the presence of either of the two serologic mark-
ers used for blood donor screening, namely HBsAg
(produced by "Hepanostika-Biomerieux") or anti-HBc
IgM+IgG (produced by "Ortho Diagnostics"), confirmed
by at least one positive test result on subsequent serologic
testing with the same markers. The cohorts were matched
by sex, age and municipality of residence.
The vaccinated cohort was recruited from an earlier study
on seroconversion [7]. The inclusion criteria for both
cohorts were having done at least two blood donations
during the period of the study (1998–2002) and being
between 18 and 65 years of age. For the vaccinated cohort,
an additional requirement was that the blood donors
seroconverted after three doses of anti-HBV DNA-recom-
binant vaccine ("Engerix-B®" – SmithKline Beecham Bio-
logicals; "Euvax-B®" – LG Chemical, Korea; "ButaNG®" –
Instituto Butantã, São Paulo, Brazil), with the second and
third dose following one and six months after the first
dose, respectively. The seroconversion criterion was
obtaining the titre of at least 10 UI/l of antibody to HBsAg
(test anti-Hbs produced by "Biomerieux") three months
after receiving the last dose of the vaccine.
For each eligible vaccinated donor, non-vaccinated
donors were looked after within the same age band (18–
29, 30–44, 45–65 years), of the same sex, and in the same
municipality. If no sex by age pair could be found in the
same municipality, an adjacent municipality of residence
was searched to obtain this matching. All blood dona-
tions were realized in the blood bank in Joaçaba, a county
capital situated in an area endemic with hepatitis B.
For the vaccinated donors, the individual contribution to
person-time incidence denominator was calculated as the
difference between the date of last blood donation and
the date last dose of anti-HBV vaccine was applied. For the
non-vaccinated donors, the individual person-time con-
tribution was the difference between the dates of the last
and the first donation during the study period. If HBV
infection occurred, person-time denominators were
reduced by half-time between the positive serologic test
result and the last seronegative donation [13].
The sample size calculation was based on the incidence
ratio of 19:1 for the non-vaccinated against the vaccinated
cohort, derived from the reported anti-HBV vaccine effi-
cacy of approximately 95% (against remaining 5% in the
same group), the HBV incidence in the non-vaccinated
blood donors of 0.67% in the Joaçaba blood bank [14],
and errors type I and II of 5% and 20%, respectively.
Assuming these parameters and equal person-timeBMC Infectious Diseases 2007, 7:124 http://www.biomedcentral.com/1471-2334/7/124
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denominator for both cohorts, Breslow-Day method
resulted in 2148 person-years and at least 4 HBV cases
between the cohorts [15].
Statistical analysis used Stata [16] and WINPEPI [15], with
mid-P method to calculate the 95% confidence intervals
(CI) and Pearson's chi-square test for significance of the
differences between the blood donors' baseline character-
istics.
Results
Total follow-up time of 1411 study participants was 4472
person-years, with average follow-up of 3.17 person-years
for all repeat donors and 2.42 and 3.94 person-years for
non-vaccinated and vaccinated donors, respectively.
Baseline differences between cohorts
The distribution of risk factors for HBV was similar among
vaccinated donors included and excluded from the analy-
sis of vaccine effectiveness, except for larger percentages of
donors with frequent donations prior to the study (chi-
square of 535 with 3 degrees of freedom and p < 0.01) and
those residing in the county capital (chi-square of 91 with
2 degrees of freedom and p < 0.01) (Table 1).
Among repeat donors included in the analysis of vaccine
effectiveness, it is worth noticing a higher percentage of
vaccinated (56.2%) than non-vaccinated (37.7%) resid-
ing in the county capital, as well as a higher number of fre-
quent donors among the former compared to the latter
(Table 1). Consequently, average interval between dona-
tions was significantly longer among the non-vaccinated
(0.62 years, 95% CI from 0.58 to 0.65 years) compared to
the vaccinated donors (0.46 years, 95% CI from 0.43 to
0.50 years).
Anti-HBV vaccine effectiveness
Anti-HBV vaccine effectiveness was calculated as one
minus the incidence ratio of vaccinated to non-vaccinated
donors. The vaccine was 100% effective, with 95% CI
from 30.1% to 100% (Table 2).
The difference in HBV incidence between the cohorts
compared was 2.33 (95% CI from 0.05 to 4.62) per thou-
sand person-years. From the perspective of the number
necessary to treat (NNT), it would be necessary to vacci-
nate 429 (95% CI from 217 to 21422) blood donors to
avoid one HBV infection in this population.
In order to verify possible confounding due to the two
HBV risk factors found to be significantly different
between the cohorts compared, a stratified analysis cross-
ing all levels of these two factors was performed. This
resulted in 12 strata (4 levels of the number of prior blood
donations crossed with 3 levels of the residence area). No
statistically significant difference (p < 0.05) of the differ-
Table 1: Blood donor characteristics regarding main confounding factors, vaccination and inclusion criteria
Risk factors Included in the analysis Excluded from the analysis
Variables Categories Non-vaccinated 
repeat donors
Vaccinated 
repeat donors
Vaccinated 
non-repeat 
donors
Vaccinated 
donors lost 
to follow-up
n% n % n % n %
Age bands (years) 18–29 112 15.7 105 15.0 26 12.7 18 16.4
30–44 351 49.2 323 46.3 106 52.0 56 50.9
45+ 250 35.1 270 38.7 72 35.3 36 32.7
Sex Masculine 376 52.7 377 54.0 113 55.4 51 46.4
Feminine 337 47.3 321 46.0 91 44.6 59 53.6
Marrital status Single 169 23.7 179 25.6 5 20.8 40 36.4
Married 484 67.9 470 67.3 16 66.7 67 60.9
Separated 12 1.7 13 1.9 1 4.2 2 1.8
Widowed 24 3.4 19 2.7 2 8.33 1 0.9
Other 24 3.6 17 2.4 0 0.0 0 0.0
Municipality of residence County capital 269 37.7 392 56.2 78 38.2 40 36.4
Other cities * 175 24.5 51 7.3 31 15.2 20 18.2
Mainly rural ** 269 37.7 255 36.5 95 46.6 50 45.4
Number of donations prior to study 1–2 120 16.8 40 5.7 8 33.3 59 54.6
3–5 403 56.5 89 12.7 13 54.2 34 31.5
6–10 169 23.7 224 32.1 2 8.33 9 8.33
>10 21 2.9 345 49.4 1 4.2 6 5.6
* with at least 20,000 inhabitants
** less than 20,000 inhabitantsBMC Infectious Diseases 2007, 7:124 http://www.biomedcentral.com/1471-2334/7/124
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ence in HBV incidence between the vaccinated and the
non-vaccinated cohort was found either within any of the
12 strata analysed separately or for the Maentel-Hanzel
pooled estimate (mean difference -9.82 with 95% CI from
-21.19 to 1.54).
Discussion
The results of this study showed excellent effectiveness of
DNA-recombinant anti-HBV vaccines in blood donors,
similarly to the results in the general population [17-20].
Wide confidence intervals for the vaccine effectiveness are
probably due to the very small numbers in the incidence
numerators natural for rare events and presence of other
factors influencing the vaccine effectiveness in a health
care setting which are better controlled for or balanced out
in a clinical trial setting.
The countries that implemented a large scale vaccination
against HBV and maintained it for at least a decade man-
aged to reduce the HBV incidence more than ten times
during this period [17-20]. Brazilian Ministry of Health
has recently introduced a similar anti-HBV vaccination
program with mandatory vaccination for children and
adolescents up to 15 years of age [8]. However, only chil-
dren in the first year of life have had reasonable vaccine
coverage, thus leaving a vast majority of the population,
including blood donors, unprotected against HBV. A
catch-up vaccination campaign would be appropriate to
accelerate the reduction of HBV in the general population.
In addition, Brazilian blood donors should be systemati-
cally encouraged to get vaccinated with DNA-recom-
binant anti-hepatitis B vaccine. Although this group has
been clearly emphasised in the recent vaccination guide-
lines [8], the logistics necessary to meet this target have
not been reinforced nationwide, so it is basically up to a
blood donor to seek a primary care unit and solicitate
anti-HBV vaccination on individual basis.
Several limitations of this study should be born in mind.
First, although matching by sex and age has likely
removed major confounding factors and the stratified
analysis confirmed the main results of the study, it is still
possible that residual confounding factors such as motiva-
tion to donate blood have not been fully accounted for in
the analysis. For example, the motivation to donate blood
repeatedly is known to be associated with lower chances
of being infected with HBV compared to first-time blood
donors. A prospective cohort study would have better
means of controlling for this factor. Second, the absence
of HBsAg positive result in the early phase of HBV infec-
tion may be as high as 25% [13], thus leaving a period of
several months before anti-HBC becomes detectable by
routine serologic testing in blood banks for a considerable
proportion of donors. During this period, neither of these
two HBV markers can detect the virus, leading to underes-
timation of the true HBV incidence. Third, very few cases
of HBV seroconversion, as well as the fact that all of them
occurred in the non-vaccinated cohort, reduced the statis-
tical power to estimate vaccine effectiveness with preci-
sion, thus leading to wide confidence intervals. Small
number of the events of interest was also prohibitive for
the applicability of time-to-event multivariate regression
methods, capable of a more precise statistical adjustment
for relevant covariates than the univariate matched group
analysis used in this study. Fourth, the blood donors
resided in an endemic area for HBV where the infection
rate in adult population is likely to be high, as indicated
by the HBV incidence of 2.33 per thousand person-years
observed in the non-vaccinated cohort. An incidence of
this order could be significantly reduced by vaccination
compared to the impact of vaccination in low endemic
areas, therefore limiting the generalisability of anti-HBV
vaccine effectiveness from this study to such areas.
Despite the limitations, this is the first study of anti-HBV
vaccine effectiveness in blood donors using a cohort study
with matched control group to minimize the impact of
confounding factors. The same methodology can be
applied to other blood banks without interfering with
their daily routine. A multi-centre evaluation of anti-HBV
vaccine effectiveness can be set up on a regular basis with
this study design, providing important information about
the reduction of HBV infection in the adult population.
In a wider perspective, it should be borne in mind that the
results of this study have demonstrated medium term pro-
tective effects of DNA-recombinant anti-HBV vaccines in
blood donors as means of reducing the transfusion-trans-
mitted HBV in Brazil. At present, long term benefits of a
widespread anti-HBV vaccination in Brazil cannot be eval-
Table 2: Effectiveness of anti-HBV vaccine, incidence ratio (IR) and 95% confidence interval (CI)
Cohort HBV cases Total follow-up 
(person-years)
Person-years at risk* Incidence per thousand 
person-years
IR (95% CI)
Vaccinated 0 2747 2715 0.00 0 (0.000, 0.696)
Non-vaccinated 4 1725 1717 2.33 1.000 **
* see methods section for calculation details
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uated because vast majority of the vaccinees have not yet
reached the minimum age for blood donation (18 years).
As government-sponsored mass vaccination against HBV
has started approximately a decade ago and has so far
achieved reasonable vaccine coverage only for the chil-
dren in the first year of life, blood donor population in
Brazil continues exposed to HBV. This underlies the need
for targeted vaccination of blood donors in addition to
the children and adolescent vaccination.
Conclusion
The results showed a very high effectiveness of DNA-
recombinant anti-hepatitis B vaccination among blood
donors resulting in the enhancement of blood recipient
safety in the State of Santa Catarina. Considerable varia-
tion of this estimate is likely due to the limited follow-up
and the influence of confounding factors normally bal-
anced out in efficacy clinical trials.
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